Neuromyelitis Optica Spectrum Disorder - Opportunity Assessment and Forecast to 2030
DESCRIPTION
TABLE OF CONTENTS
RELATED REPORTS
SAMPLE REQUEST
REVIEWS
DESCRIPTION
Neuromyelitis Optica Spectrum Disorder - Opportunity Assessment and Forecast to 2030
Summary
Neuromyelitis optica spectrum disorder (NMOSD) is a rare, chronic, neurological autoimmune disorder that primarily affects the brain and the spinal cord. NMOSD was previously referred to as neuromyelitis optica (NMO) disease or Devics syndrome. Patients with NMOSD develop optic neuritis (ON), which causes pain in the eye and can lead to vision loss. They also develop longitudinally extensive transverse myelitis (LETM), which results in weakness or paralysis of arms and legs associated with painful spasms, loss of sensation, uncontrollable vomiting and hiccups, and loss of bladder and bowel control.
The two clinically and commercially relevant phenotypes considered for the classification of NMOSD in this report are anti-AQP4+ NMOSD and anti-AQP4- NMOSD.
The majority of NMOSD patients suffer recurrent severe attacks or relapses following the initial attack, therefore patients are given long-term preventative treatment.
Key Highlights
- Forecasts include one country
- Forecasts cover three time points: base year, 5-year, and 10-year
- The prevalence of NMOSD is increasing in line with population growth in China.
- Major unmet needs are expected to be partially addressed by 2030, however, the opportunity to develop a curative drug remains.
- The NMOSD pipeline is dominated by innovative biologics that are looking to suppress the risk of relapses and disabilities.
- NMOSD market will exhibit significant growth between 2020 and 2030, driven by the launches of late-stage pipeline agents and the anticipated increased reimbursement
Scope
- Overview of NMOSD, including epidemiology, symptoms, diagnosis, and disease management.
- Annualized NMOSD therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in two patient segments (anti-AQP4+ NMOSD and anti-AQP4- NMOSD) forecast from 2020 to 2030.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the NMOSD therapeutics market.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for NMOSD therapy. The most promising candidates in Phase III development are profiled.
- Analysis of the current and future market competition in the global NMOSD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global NMOSD therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the NMOSD therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Summary
Neuromyelitis optica spectrum disorder (NMOSD) is a rare, chronic, neurological autoimmune disorder that primarily affects the brain and the spinal cord. NMOSD was previously referred to as neuromyelitis optica (NMO) disease or Devics syndrome. Patients with NMOSD develop optic neuritis (ON), which causes pain in the eye and can lead to vision loss. They also develop longitudinally extensive transverse myelitis (LETM), which results in weakness or paralysis of arms and legs associated with painful spasms, loss of sensation, uncontrollable vomiting and hiccups, and loss of bladder and bowel control.
The two clinically and commercially relevant phenotypes considered for the classification of NMOSD in this report are anti-AQP4+ NMOSD and anti-AQP4- NMOSD.
The majority of NMOSD patients suffer recurrent severe attacks or relapses following the initial attack, therefore patients are given long-term preventative treatment.
Key Highlights
- Forecasts include one country
- Forecasts cover three time points: base year, 5-year, and 10-year
- The prevalence of NMOSD is increasing in line with population growth in China.
- Major unmet needs are expected to be partially addressed by 2030, however, the opportunity to develop a curative drug remains.
- The NMOSD pipeline is dominated by innovative biologics that are looking to suppress the risk of relapses and disabilities.
- NMOSD market will exhibit significant growth between 2020 and 2030, driven by the launches of late-stage pipeline agents and the anticipated increased reimbursement
Scope
- Overview of NMOSD, including epidemiology, symptoms, diagnosis, and disease management.
- Annualized NMOSD therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in two patient segments (anti-AQP4+ NMOSD and anti-AQP4- NMOSD) forecast from 2020 to 2030.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the NMOSD therapeutics market.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for NMOSD therapy. The most promising candidates in Phase III development are profiled.
- Analysis of the current and future market competition in the global NMOSD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global NMOSD therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the NMOSD therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
TABLE OF CONTENTS
1. Executive Summary
1.1 Executive Summary
2. Disease Overview
2.1 Overview of Neuromyelitis Optica Spectrum Disorder
2.2 Neuromyelitis Optica Spectrum Disorder SWOT Analysis
2.3 Classification of Neuromyelitis Optica Spectrum Disorder
3. Epidemiology
3.1 Diagnosed Prevalent Cases of Neuromyelitis Optica Spectrum Disorder, 2020-2030
3.2 Diagnosed Prevalent Cases of Neuromyelitis Optica Spectrum Disorder by Types, All Ages, N, 2020
3.3 Sources and Methodology for Diagnosed Prevalent Cases of NMOSD and Diagnosed Prevalent Cases of NMOSD by Phenotype
3.4 Sources and Methodology - Diagnosed Prevalent Cases of NMOSD and Diagnosed Prevalent Cases of NMOSD by Phenotype
4. Current Treatment Options
4.1 Treatment Paradigm
4.2 Marketed Products
4.3 Product Profile: Corticosteroids (Methylprednisolone and Prednisone)
4.4 Product Profile: Azathioprine (AZA)
4.5 Product Profile: Mycophenolate mofetil (MMF)
4.6 Product Profile: Roches Rituxan/ MabThera (rituximab)
4.7 Product Profile: Alexion Pharmaceuticals (Shanghai) Soliris (eculizumab)
4.8 Product Profile: Shanghai Roches Enspryng (satralizumab)
5. Unmet Needs and Opportunities
5.1 Unmet Needs in Neuromyelitis Optica Spectrum Disorder
6. R&D Strategies
6.1 Trends in Clinical Trial Design in Neuromyelitis Optica Spectrum Disorder
6.2 Trends in Deal-Making in Neuromyelitis Optica Spectrum Disorder
7. Pipeline Assessment
7.1 Neuromyelitis Optica Spectrum Disorder Pipeline Overview
7.3 Late-Stage Pipeline Agents
7.3 Product Profile: Mitsubishi Tanabe/Viela Bios Uplizna (inebilizumab)
7.4 Product Profile: Yantai Rongchang/RemeGen Telitacicept
7.5 Product profile: Alexions Ultomiris (ravulizumab)
8. Market Outlook
8.1 Neuromyelitis Optica Spectrum Disorder Market Forecast
8.2 Market Drivers and Barriers
9. Appendix
9.1 Primary Research: KOL Information
9.2 Bibliography
9.3 About the Authors
10. Contact Us
RELATED REPORTS
Neuromyelitis Optica Spectrum Disorders (NMOSD) Market in China 2023
Neuromyelitis optica spectrum disorders (NMOSD) are a group of rare autoimmune diseases that affect the central nervous system, particularly the optic nerves and spinal cord. NMOSD is characterized by recurrent
View ReportNeuromyelitis Optica (Devic’s Syndrome) - Global Clinical Trials Review, H2, 2021
Neuromyelitis Optica (Devics Syndrome) - Global Clinical Trials Review, H2, 2021GlobalDatas clinical trial report, Neuromyelitis Optica (Devics Syndrome) - Global Clinical Trials Review, H2, 2021 provides an overview of Neuromyelitis
View ReportNeuromyelitis Optica Spectrum Disorders (NMOSD) Market in China 2023
Neuromyelitis optica spectrum disorders (NMOSD) are a group of rare autoimmune diseases that affect the central nervous system, particularly the optic nerves and spinal cord. NMOSD is characterized by recurrent
View ReportNeuromyelitis Optica (Devic’s Syndrome) - Global Clinical Trials Review, H2, 2021
Neuromyelitis Optica (Devics Syndrome) - Global Clinical Trials Review, H2, 2021GlobalDatas clinical trial report, Neuromyelitis Optica (Devics Syndrome) - Global Clinical Trials Review, H2, 2021 provides an overview of Neuromyelitis
View ReportSAMPLE REQUEST
Fill The Form For Sample Request
REVIEWS
